| Autor: |
Punter KB; Department of Biomedical and Medical Sciences, Queen's University, Kingston, Canada., Chu C; Department of Biomedical and Medical Sciences, Queen's University, Kingston, Canada., Chan EYW; Department of Biomedical and Medical Sciences, Queen's University, Kingston, Canada. |
| Jazyk: |
angličtina |
| Zdroj: |
Endocrine-related cancer [Endocr Relat Cancer] 2022 Dec 13; Vol. 30 (1). Date of Electronic Publication: 2022 Dec 13 (Print Publication: 2023). |
| DOI: |
10.1530/ERC-22-0229 |
| Abstrakt: |
It has long been recognised that cancer cells critically depend on reprogrammed patterns of metabolism that can enable robust and abnormally high levels of cell proliferation. As mitochondria form hubs of cellular metabolic activity, it is reasonable to propose that pathways within these organelles can form targets that can be manipulated to compromise the ability of cancer cells to cause disease. However, mitochondria are highly multi-functional, and the full range of mechanistic inter-connections are still being unravelled to enable the full potential of targeting mitochondria in cancer therapeutics. Here, we aim to highlight the potential of modulating mitochondrial dynamics to target key metabolic or apoptotic pathways in cancer cells. Distinct roles have been demonstrated for mitochondrial fission and fusion in different cancer contexts. Targeting of factors mediating mitochondrial dynamics may be directly related to impairment of oxidative phosphorylation, which is essential to sustain cancer cell growth and can also alter sensitivity to chemotherapeutic compounds. This area is still lacking a unified model, although further investigation will more comprehensively map the underlying molecular mechanisms to enable better rational therapeutic strategies based on these pathways. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
